Breast Cancer Therapeutics in Major Developed Markets Trends to 2021 2

Breast Cancer Therapeutics in Major Developed
Markets to 2021 - Growth Driven by Rapid
Uptake of Premium Priced Biologics and Rising
Incidence
No of Pages – 170
Publishing Date - December 15, 2015
Browse detailed TOC, Tables, Figures, Charts in Breast Cancer Therapeutics in Major
Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics
and Rising Incidence at- http://www.absolutereports.com/10070569
Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake
of Premium Priced Biologics and Rising Incidence

Summary

Breast cancer, a malignant neoplasm, is the second most common cancer and the most common
cancer in women worldwide, accounting for 16% of all female cancers, making the disease
exceedingly prevalent. The number of women diagnosed with breast cancer has increased over the
past few decades, but the number of deaths has declined due to earlier diagnosis and better treatment
options.

Breast cancer treatment has been revolutionized in the past four decades, especially with increasing
usage of targeted therapies. The marketed products landscape comprises a wide range of treatment
options, including hormonal therapies, chemotherapies, combination therapies, and targeted
therapies. Nevertheless, significant unmet need remains for products that can improve overall
survival rate, time to disease progression, and overall response.

Scope

The current breast cancer market contains novel products, including Perjeta, a targeted therapy;
Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent.